hero section gradient
15 handpicked stocks

Clean Living

Tap into the growing movement toward natural products and wellness. This carefully selected group of stocks represents companies dedicated to providing pure, organic, and non-toxic alternatives across food, personal care, and household goods.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Market capitalisation breakdown for the Clean Living stock basket, sorted largest to smallest.

Key Takeaways for Investors:
  • Large-cap dominance tends to reduce volatility, offering more stable returns and closer tracking to broad-market performance.
  • Suitable as a core portfolio holding rather than a speculative, high-growth allocation.
  • Expect steady long-term appreciation rather than explosive short-term gains; patience and diversification remain important.
Total Market Cap
  • HNST: $396.12M

  • SFM: $10.75B

  • NGVC: $915.18M

  • Other

About This Group of Stocks

1

Our Expert Thinking

These companies are riding a powerful wave of consumer demand for health, transparency, and sustainability. We've identified businesses at the intersection of wellness and consumerism that stand to benefit from the growing preference for clean, natural alternatives to traditional products.

2

What You Need to Know

This collection spans multiple industries including organic grocers, natural personal care makers, and wellness product manufacturers. All share a common focus: providing goods that support a healthier lifestyle free from artificial additives and harsh chemicals.

3

Why These Stocks

We've selected companies that derive significant revenue from natural, organic, or sustainable goods. Each business has authentically positioned itself in the clean living space, excluding those heavily reliant on artificial or highly processed inputs.

Why You'll Want to Watch These Stocks

📈

Riding the Wellness Wave

Health consciousness is at an all-time high, with consumers increasingly willing to pay premium prices for products they believe support their wellbeing and align with their values.

🔍

Label Scrutiny Pays Off

As more shoppers carefully examine ingredient lists and demand transparency, these companies are positioned to benefit from the shift away from artificial additives and chemicals.

🌱

Growth in Natural Markets

The clean living sector continues to expand as mainstream consumers adopt practices once considered niche. These companies are at the forefront of this transition to natural alternatives.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions